Clinical Trials

As AN2 Therapeutics bets its future on novel boron-based drugs, the appointment of Dr. Cameron Trenor signals a critical shift from promise to proof.

A $1M award for a novel drug targeting mitochondrial dysfunction is more than just funding; it's a bet on a new paradigm for fighting neurodegeneration.

With federal funds backing its Phase 3 trial for a first-in-class cannabis withdrawal drug, PleoPharma offers a new model for biotech investment.

A 645% surge in contracts is just the headline. The real story is how NetraMark's 'explainable' AI is building trust and changing how we develop new cures.

With positive Phase 1 results, AC Immune's NLRP3 inhibitor not only targets neuro-inflammation but also bolsters the company's independent strategy.

Low patient enrollment cripples cancer research. Mednet’s new AI tool, TrialMatch, aims to fix this by seamlessly connecting oncologists to vital trials.

A novel therapy that disarms rather than kills a deadly superbug offers a glimpse of a post-antibiotic future for patients with a debilitating lung disease.

An acquisition signals more than growth; it’s a strategic redesign of the clinical trial landscape, challenging giants and empowering innovation.

By appointing Merck and Pfizer heavyweight Dr. David Strutton, Crescendo Health signals a major bid to monetize patient-centric data in the booming RWE market.

A landmark study validates Kandu's at-home IpsiHand, showing over half of chronic stroke patients can regain meaningful hand function years after injury.

A top exec's move from a device giant to a drug startup signals a major shift. Charles Anderson analyzes why hardware's limits in fighting infection are now biotech's biggest opportunity.

Coultreon Biopharma's strategic hire of Dr. Prista Charuworn signals a major push to advance its novel SIK3 inhibitor in the crowded autoimmune market.

The dermatology giant posts strong revenue but dips in profit, channeling funds into high-impact acquisitions and R&D for underserved skin conditions.

A Boston biotech with Korean roots just went public in Seoul. Its goal: to repair the body's smallest blood vessels, a market Merck has already bet billions on.

Quoin Pharmaceuticals scores key regulatory wins for its rare skin disease drugs, offering hope where none existed. But can its cash hold out long enough?

Quince Therapeutics bets its future on an inhaled lung disease drug, LAM-001, after acquiring Orphai and securing a $115M financing to fuel its new mission.

Fortress Biotech's Q2 net loss masks a cash-rich strategy. A $117M cash surge and major pipeline wins reveal a model built for the long haul.

Kyntra Bio's Q2 profit was driven by a one-time accounting gain, masking operating losses. Now, the firm bets its future on two critical Q4 data readouts.

With a cash runway to 2029 and a novel cancer drug nearing key data, NuCana signals quiet confidence in a high-stakes race to treat resistant melanoma.

With a $115M financing and an expanded pipeline, Assembly Biosciences is betting on novel therapies for liver and viral diseases. But can it navigate a crowded field?